Loading
ALA-105 is an experimental CAR-iNKT cell therapy with IL-12 armouring from Arovella Therapeutics, at a stage the company does not state for gastric cancer, gastro-oesophageal junction cancer and pancreatic cancer.
ALA-105 (CLDN18.2-iNKT) is a CAR-iNKT cell therapy with IL-12 armouring from Arovella Therapeutics, with Sparx Group as partner. iNKT cells carrying a CAR built from Sparx's anti-CLDN18.2 antibody SPX-101, armoured with membrane-tethered IL-12 (IL-12-TM) to improve persistence in solid tumours. The company does not state its stage; it is aimed at gastric cancer, gastro-oesophageal junction cancer and pancreatic cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registry trial found (ClinicalTrials.gov query for ALA-105 returned none); the company page gives no stage, so 'preclinical' is inferred from the absence of any trial. It has not been shown to work in people.
iNKT cells carrying a CAR built from Sparx's anti-CLDN18.2 antibody SPX-101, armoured with membrane-tethered IL-12 (IL-12-TM) to improve persistence in solid tumours. Connects to Claudin 18.2.
1.ALA-105 slips into a pocket on Claudin 18.2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ALA-105" OR ABSTRACT:"ALA-105" OR TITLE:"CLDN18.2-iNKT" OR ABSTRACT:"CLDN18.2-iNKT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALA-105, not a curated reading list.
Shares Arovella Therapeutics and the tag pipeline.
Shares Arovella Therapeutics and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Shares Claudin 18.2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/